ImmuCell CorporationICCCNASDAQ
Loading
Operating Cash Flow Growth Recovery in ProgressRecovering
Percentile Rank33
Year-over-Year Change
Year-over-year operating cash flow growth rate
Percentile
P33
Within normal range
vs 5Y Ago
-0.6x
Contraction
Streak
1 qtr
Consecutive growthRecovering
| Period | Value |
|---|---|
| Q4 2025 | -68.51% |
| Q3 2025 | -173.84% |
| Q2 2025 | 1.76% |
| Q1 2025 | 51684.27% |
| Q4 2024 | 99.52% |
| Q3 2024 | -209.89% |
| Q2 2024 | 39.01% |
| Q1 2024 | 157.88% |
| Q4 2023 | -42.41% |
| Q3 2023 | 25.49% |
| Q2 2023 | 75.33% |
| Q1 2023 | -112.82% |
| Q4 2022 | -3.16% |
| Q3 2022 | -436.86% |
| Q2 2022 | -41.51% |
| Q1 2022 | 8.61% |
| Q4 2021 | 126.99% |
| Q3 2021 | -64.56% |
| Q2 2021 | 217.21% |
| Q1 2021 | -499.07% |
| Q4 2020 | 123.41% |
| Q3 2020 | -168.85% |
| Q2 2020 | 13.03% |
| Q1 2020 | 1939.16% |
| Q4 2019 | 29.79% |
| Q3 2019 | 79.92% |
| Q2 2019 | -148.83% |
| Q1 2019 | 589.49% |
| Q4 2018 | 72.66% |
| Q3 2018 | -2484.36% |
| Q2 2018 | -91.50% |
| Q1 2018 | -24.51% |
| Q4 2017 | 231.57% |
| Q3 2017 | -62.04% |
| Q2 2017 | -112.39% |
| Q1 2017 | 436.41% |
| Q4 2016 | -215.52% |
| Q3 2016 | -146.55% |
| Q2 2016 | 390.34% |
| Q1 2016 | -110.51% |